Indeed, the knowledge of KRAS mutational status of a primary tumour is now mandatory for the treatment of metastatic disease, as it is a predictor of resistance to monoclonal antibodies of the epidermal growth factor receptor (anti-EGFR moAbs) (Bokemeyer et al, 2008; Douillard et al, 2009; Hecht et al, 2009; Tol et al, 2009; Van Cutsem et al, 2009). Here, EGFR is linked to metastatic neoplasm.